Contact-facilitated drug delivery with Sn2 lipase labile prodrugs optimize targeted lipid nanoparticle drug delivery

Dipanjan Pan, Christine T N Pham, Katherine N. Weilbaecher, Michael H. Tomasson, Samuel A. Wickline, Gregory M. Lanza

Research output: Contribution to journalReview article

Abstract

Sn2 lipase labile phospholipid prodrugs in conjunction with contact-facilitated drug delivery offer an important advancement in Nanomedicine. Many drugs incorporated into nanosystems, targeted or not, are substantially lost during circulation to the target. However, favorably altering the pharmacokinetics and volume of distribution of systemic drug delivery can offer greater efficacy with lower toxicity, leading to new prolonged-release nanoexcipients. However, the concept of achieving Paul Erhlich's inspired vision of a 'magic bullet' to treat disease has been largely unrealized due to unstable nanomedicines, nanosystems achieving low drug delivery to target cells, poor intracellular bioavailability of endocytosed nanoparticle payloads, and the substantial biological barriers of extravascular particle penetration into pathological sites. As shown here, Sn2 phospholipid prodrugs in conjunction with contact-facilitated drug delivery prevent premature drug diffusional loss during circulation and increase target cell bioavailability. The Sn2 phospholipid prodrug approach applies equally well for vascular constrained lipid-encapsulated particles and micelles the size of proteins that penetrate through naturally fenestrated endothelium in the bone marrow or thin-walled venules of an inflamed microcirculation. At one time Nanomedicine was considered a 'Grail Quest' by its loyal opposition and even many in the field adsorbing the pains of a long-learning curve about human biology and particles. However, Nanomedicine with innovations like Sn2 phospholipid prodrugs has finally made 'made the turn' toward meaningful translational success.

Original languageEnglish (US)
Pages (from-to)85-106
Number of pages22
JournalWiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology
Volume8
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Medical nanotechnology
Phospholipids
Prodrugs
Lipases
Lipase
Drug delivery
Nanoparticles
Lipids
Nanomedicine
Nanosystems
Pharmaceutical Preparations
Microcirculation
Biological Availability
Pharmacokinetics
Micelles
Particles (particulate matter)
Toxicity
Bone
Magic
Learning Curve

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Biomedical Engineering

Cite this

Contact-facilitated drug delivery with Sn2 lipase labile prodrugs optimize targeted lipid nanoparticle drug delivery. / Pan, Dipanjan; Pham, Christine T N; Weilbaecher, Katherine N.; Tomasson, Michael H.; Wickline, Samuel A.; Lanza, Gregory M.

In: Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, Vol. 8, No. 1, 01.01.2016, p. 85-106.

Research output: Contribution to journalReview article

Pan, Dipanjan ; Pham, Christine T N ; Weilbaecher, Katherine N. ; Tomasson, Michael H. ; Wickline, Samuel A. ; Lanza, Gregory M. / Contact-facilitated drug delivery with Sn2 lipase labile prodrugs optimize targeted lipid nanoparticle drug delivery. In: Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 2016 ; Vol. 8, No. 1. pp. 85-106.
@article{5c73a39637e643a99e49d1bbf14c778d,
title = "Contact-facilitated drug delivery with Sn2 lipase labile prodrugs optimize targeted lipid nanoparticle drug delivery",
abstract = "Sn2 lipase labile phospholipid prodrugs in conjunction with contact-facilitated drug delivery offer an important advancement in Nanomedicine. Many drugs incorporated into nanosystems, targeted or not, are substantially lost during circulation to the target. However, favorably altering the pharmacokinetics and volume of distribution of systemic drug delivery can offer greater efficacy with lower toxicity, leading to new prolonged-release nanoexcipients. However, the concept of achieving Paul Erhlich's inspired vision of a 'magic bullet' to treat disease has been largely unrealized due to unstable nanomedicines, nanosystems achieving low drug delivery to target cells, poor intracellular bioavailability of endocytosed nanoparticle payloads, and the substantial biological barriers of extravascular particle penetration into pathological sites. As shown here, Sn2 phospholipid prodrugs in conjunction with contact-facilitated drug delivery prevent premature drug diffusional loss during circulation and increase target cell bioavailability. The Sn2 phospholipid prodrug approach applies equally well for vascular constrained lipid-encapsulated particles and micelles the size of proteins that penetrate through naturally fenestrated endothelium in the bone marrow or thin-walled venules of an inflamed microcirculation. At one time Nanomedicine was considered a 'Grail Quest' by its loyal opposition and even many in the field adsorbing the pains of a long-learning curve about human biology and particles. However, Nanomedicine with innovations like Sn2 phospholipid prodrugs has finally made 'made the turn' toward meaningful translational success.",
author = "Dipanjan Pan and Pham, {Christine T N} and Weilbaecher, {Katherine N.} and Tomasson, {Michael H.} and Wickline, {Samuel A.} and Lanza, {Gregory M.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1002/wnan.1355",
language = "English (US)",
volume = "8",
pages = "85--106",
journal = "Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology",
issn = "1939-0041",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Contact-facilitated drug delivery with Sn2 lipase labile prodrugs optimize targeted lipid nanoparticle drug delivery

AU - Pan, Dipanjan

AU - Pham, Christine T N

AU - Weilbaecher, Katherine N.

AU - Tomasson, Michael H.

AU - Wickline, Samuel A.

AU - Lanza, Gregory M.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Sn2 lipase labile phospholipid prodrugs in conjunction with contact-facilitated drug delivery offer an important advancement in Nanomedicine. Many drugs incorporated into nanosystems, targeted or not, are substantially lost during circulation to the target. However, favorably altering the pharmacokinetics and volume of distribution of systemic drug delivery can offer greater efficacy with lower toxicity, leading to new prolonged-release nanoexcipients. However, the concept of achieving Paul Erhlich's inspired vision of a 'magic bullet' to treat disease has been largely unrealized due to unstable nanomedicines, nanosystems achieving low drug delivery to target cells, poor intracellular bioavailability of endocytosed nanoparticle payloads, and the substantial biological barriers of extravascular particle penetration into pathological sites. As shown here, Sn2 phospholipid prodrugs in conjunction with contact-facilitated drug delivery prevent premature drug diffusional loss during circulation and increase target cell bioavailability. The Sn2 phospholipid prodrug approach applies equally well for vascular constrained lipid-encapsulated particles and micelles the size of proteins that penetrate through naturally fenestrated endothelium in the bone marrow or thin-walled venules of an inflamed microcirculation. At one time Nanomedicine was considered a 'Grail Quest' by its loyal opposition and even many in the field adsorbing the pains of a long-learning curve about human biology and particles. However, Nanomedicine with innovations like Sn2 phospholipid prodrugs has finally made 'made the turn' toward meaningful translational success.

AB - Sn2 lipase labile phospholipid prodrugs in conjunction with contact-facilitated drug delivery offer an important advancement in Nanomedicine. Many drugs incorporated into nanosystems, targeted or not, are substantially lost during circulation to the target. However, favorably altering the pharmacokinetics and volume of distribution of systemic drug delivery can offer greater efficacy with lower toxicity, leading to new prolonged-release nanoexcipients. However, the concept of achieving Paul Erhlich's inspired vision of a 'magic bullet' to treat disease has been largely unrealized due to unstable nanomedicines, nanosystems achieving low drug delivery to target cells, poor intracellular bioavailability of endocytosed nanoparticle payloads, and the substantial biological barriers of extravascular particle penetration into pathological sites. As shown here, Sn2 phospholipid prodrugs in conjunction with contact-facilitated drug delivery prevent premature drug diffusional loss during circulation and increase target cell bioavailability. The Sn2 phospholipid prodrug approach applies equally well for vascular constrained lipid-encapsulated particles and micelles the size of proteins that penetrate through naturally fenestrated endothelium in the bone marrow or thin-walled venules of an inflamed microcirculation. At one time Nanomedicine was considered a 'Grail Quest' by its loyal opposition and even many in the field adsorbing the pains of a long-learning curve about human biology and particles. However, Nanomedicine with innovations like Sn2 phospholipid prodrugs has finally made 'made the turn' toward meaningful translational success.

UR - http://www.scopus.com/inward/record.url?scp=84952872447&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952872447&partnerID=8YFLogxK

U2 - 10.1002/wnan.1355

DO - 10.1002/wnan.1355

M3 - Review article

C2 - 26296541

AN - SCOPUS:84952872447

VL - 8

SP - 85

EP - 106

JO - Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

JF - Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

SN - 1939-0041

IS - 1

ER -